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Of the approximately 335 emerging infectious diseases that were iden-
tified between 1940 and 2004, 60.3% originated in wildlife1. From 
past pandemics, it is clear that highly pathogenic zoonoses are major 
threats to global human health, economic stability and national secu-
rity1–4. SARS-CoV and swine influenza virus CA/04/09 H1N1 have 
caused substantial human morbidity and mortality in the 21st century. 
Similar to influenza, CoVs have a strong history of host shifting and 
cross-species transmission5,6. In addition to the emergence of SARS-
CoV in 2002, which caused 50% mortality in aged populations, several 
other human CoVs, such as HCoV-NL63, HCoV-OC43 and HCoV-
229E, probably emerged from animal reservoirs within the past 
200 years7,8. The sudden emergence of new respiratory viral pathogens 
from animals underscores the need for new, broadly applicable vaccine 
strategies that rapidly and rationally attenuate emerging zoonoses, 
especially to protect vulnerable populations in future outbreaks.
Vaccines have a long history of success in reducing viral disease bur-
dens. Live, attenuated viruses are ideal vaccine candidates, as they elicit 
balanced innate and adaptive lifelong protective immune responses 
with low production and delivery costs9. Unfortunately, broadly appli-
cable strategies for the rational design of live, attenuated virus vaccines 
have remained elusive, and vaccines attenuated by chemical treatment 
or passage can revert to virulence, resulting in disease outbreaks in 
unvaccinated and immunocompromised populations9. Moreover, the 
precise mechanism of attenuation often remains unclear; thus, the sta-
bility of the attenuation cannot be clearly evaluated or assured.
RNA viruses encode RNA-dependent RNA polymerases that lack 
efficient proofreading capabilities; the resulting high error rates, 
which range from 10−3 to 10−5 mutations per site per round of rep-
lication, render RNA viruses highly vulnerable to lethal mutagenesis 
using chemical agents10,11. High mutation rates generate consider-
able genomic diversity, allowing RNA viruses to rapidly adapt to 
changing environmental conditions and hosts12. Increased replica-
tion fidelity has been shown to reduce the virulence of poliovirus 
and chikungunya virus12–14 and has been proposed as a strategy 
for live, attenuated virus design15. CoVs encode the largest known 
RNA virus genomes (26–32 kb), exceeding the theoretical limits 
of viable RNA genome size11. Mutation rates are lower in CoVs 
than in other RNA viruses, approaching 2 × 10−6 mutations per site 
per round of replication16. Nsp14, encoded in the viral replicase 
gene, contains a 3′→5′ exoRNase (ExoN) of the DEDDh exonu-
clease superfamily17. In addition to the CoVs, ExoN homologs are 
present in the members of the Nidovirales order, whose genomes 
are >20 kb, but are not present in the smaller arteriviruses (with 
genomes of 12–16 kb), suggesting that the ExoN had a crucial role 
in genome expansion16,18. In vitro, 3′→5′ exoRNase activity has 
been demonstrated for recombinant SARS-CoV nsp14 (ref. 19). We 
have engineered and recovered viable ExoN inactivation mutants 
from mouse hepatitis virus (MHV-ExoN) and SARS-CoV (Urbani 
background, SARS-ExoN). Both MHV-ExoN and SARS-ExoN 
inactivations are maintained stably for more than ten passages 
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Live, attenuated RNA virus vaccines are efficacious but subject to reversion to virulence. Among RNA viruses, replication fidelity 
is recognized as a key determinant of virulence and escape from antiviral therapy; increased fidelity is attenuating for some 
viruses. Coronavirus (CoV) replication fidelity is approximately 20-fold greater than that of other RNA viruses and is mediated  
by a 3′→5′ exonuclease (ExoN) activity that probably functions in RNA proofreading. In this study we demonstrate that 
engineered inactivation of severe acute respiratory syndrome (SARS)-CoV ExoN activity results in a stable mutator phenotype 
with profoundly decreased fidelity in vivo and attenuation of pathogenesis in young, aged and immunocompromised mice.  
The ExoN inactivation genotype and mutator phenotype are stable and do not revert to virulence, even after serial passage or 
long-term persistent infection in vivo. ExoN inactivation has potential for broad applications in the stable attenuation of CoVs 
and, perhaps, other RNA viruses.
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in vitro and have 15- to 20-fold increased mutation frequencies 
compared to wild-type MHV and SARS-CoV16,20. Thus, ExoN has a 
crucial role in CoV RNA genome replication fidelity in vitro, prob-
ably by directly mediating or stimulating proofreading, a function 
previously unknown among RNA viruses21.
In this study, we used the stable, low-fidelity mutator phenotype 
of the SARS-CoV ExoN mutants to determine whether decreased 
replication fidelity could be used as a rational design strategy for 
a live, attenuated vaccine with broad potential applications to 
other viruses16,20,21. We evaluated (i) the impact of the inactiva-
tion of an RNA-proofreading exonuclease and the resultant mutator 
phenotype on CoV replication, fitness and pathogenesis; (ii) virus 
stability after passage or persistence in vivo; and (iii) the efficacy of 
using a decreased-fidelity mutant as a vaccine. Further, we assessed 
the potential for generating stably attenuated, reversion-resistant, 
immunogenic strains of known and newly identified CoVs to be 
used as vaccines in both immunocompetent and immunocompro-
mised populations.
RESULTS
The mutator phenotype and decreased fitness of MA-ExoN
We engineered nsp14 ExoN inactivation mutations into the back-
ground of the virulent mouse-adapted SARS-CoV (MAwt), yielding 
MA-ExoN (Fig. 1a,b). We compared MAwt, which causes increased 
mortality and acute respiratory distress in young and aged mouse 
models22–24, and MA-ExoN in in vitro growth experiments (multi-
plicity of infection (MOI) = 0.1 PFU per cell). MA-ExoN showed a 
stable growth defect of less than 1 log (Fig. 1c). When placed in direct 
competition, MA-ExoN was clearly less fit than MAwt over successive 
rounds of infection (Supplementary Fig. 1a,b). At 6 h after infection 
(p.i.), MA-ExoN genome RNA levels were roughly equivalent to those 
of MAwt and were lower than those of MAwt at 12 h p.i.; by 24 h p.i., 
MA-ExoN genome RNA levels were approximately 10% of those of 
MAwt (Supplementary Fig. 1c). Thus, the data suggest that MA-
ExoN is able to initiate and establish replication efficiently through 
times of peak RNA synthesis (0–6 h) but has impaired accumula-
tion, which manifests late in one round of infection and is amplified 
over multiple rounds. These results are consistent with accumulating 
defects resulting from a markedly increased mutation rate (see the 
Discussion section).
We then sequenced RNA from multiple MAwt and MA-ExoN 
plaques. Both the MAwt background and engineered ExoN muta-
tions were present in all sequenced MA-ExoN clones. Additionally, 
MA-ExoN accumulated 14-fold more unique mutations and had 
a mean 11.5-fold greater mutation frequency compared to MAwt 
(P <0.01) (Fig. 1d,e). These results confirm that the growth and repli-
cation fidelity impairments of the nsp14 ExoN mutator phenotype are 
present in MA-ExoN and are indistinguishable from those in SARS-
ExoN during replication in culture.
MA-ExoN is attenuated in vivo
To assess MA-ExoN virulence, we infected young (10-week-old) and aged 
(14-month-old) female BALB/c mice with MA-ExoN or MAwt (Fig. 2). 
Young mice infected with MAwt showed dose-dependent weight loss 
and recovery (Fig. 2a), though they had no observable dose-dependent 
differences in lung titers or clearance after day 4 p.i. (Fig. 2b). In contrast, 
young mice infected with MA-ExoN showed no signs of clinical disease 
and had high but not dose-dependent lung titers that were rapidly cleared 
by day 4 p.i. (Fig. 2a,b). We then compared MA-ExoN and MAwt infec-
tion in aged, immunosenescent mice25. Mice infected with either virus 
experienced dose-dependent weight loss (Fig. 2c); however, although 
lung titers were equivalent across all doses of MA-ExoN and MAwt on 
day 2 p.i., mice infected with MA-ExoN cleared the virus independ-
ent of inoculation dose, whereas mice infected with MAwt had begun 
to clear the virus from higher-titer infections more efficiently at day 4 
p.i. than from lower-titer infections (Fig. 2d). Additionally, whereas aged 
mice infected with MA-ExoN had no mortality, MAwt-infected mice 
had dose-dependent mortality (Fig. 2e). As described previously23, we 
found little if any virus in other organs. These experiments demonstrate 
that MA-ExoN is attenuated in both young and aged diseased mice 
compared to virulent MAwt and that disease symptoms, when present, 
are less pronounced in MA-ExoN infections than MAwt infections.
A potential concern with live, attenuated vaccines is the chance that 
they could revert to virulence in vivo, particularly in immunocom-
promised individuals. Therefore, we assessed whether MA-ExoN was 
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Figure 1 The nsp14 ExoN mutator virus in a virulent mouse-adapted 
SARS-CoV isogenic background. (a) Genome organization, with the 
locations of the nsp14 coding sequence (black rectangle) and the mouse-
adapted mutations (triangles) shown. ORF1a/b, ORF1a and ORF1b. 
Structural proteins are labeled as follows: S, spike; E, envelope; M, 
membrane; N, nucleocapsid. (b) Nsp14 ExoN motifs, DEDD domain 
residues (underlined) and alanine substitutions (D90A and E92A) in  
motif I recovered in wild-type SARS-CoV and MAwt backgrounds.  
(c) Growth analysis (MOI = 0.1 PFU per cell) of wild-type SARS-CoV, 
S-ExoN, MAwt and MA-ExoN on Vero cells. Error bars, s.d. (d) Mutation 
frequency from complete genome sequencing of plaque isolates of 
MAwt and MA-ExoN (n = 5 for both) at passage 3. The increase in mean 
mutation frequency (horizontal lines) in MA-ExoN compared to MAwt 
(11.5×) is indicated. *P < 0.01 (Mann-Whitney nonparametric test 
for independent samples). (e) The mutations identified with complete 
genome sequencing across five clones from each group. Filled circles, 
nonsynonymous mutations; open circles, synonymous mutations; black, 
noncoding mutations; red, mutations present in more than one clone; 
blue, mutations present in only one clone. Mouse-adapted mutations 
are shown as triangles on the genome schematic and were present in all 
sequenced genomes.
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attenuated in immunocompromised mice. We used MAwt and MA-
ExoN to infect young Rag−/− (recombination activating gene), severe 
combined immunodeficiency (SCID) and Stat1−/− (signal transducer 
and activator of transcription 1) mice, as well as background con-
trols (C57BL/6, BALB/c and 129 mice, respectively). All MA-ExoN–
infected mice had significantly less weight loss than MAwt-infected 
mice (P < 0.05; Fig. 3a–c and Supplementary Table 1). Only Stat1−/− 
mice had any notable weight loss (~15%) as a result of MA-ExoN 
infection; however, these mice did not pass experimental morbidity 
thresholds (Fig. 3c). In contrast, all MAwt-infected Stat1−/− mice died 
or were moribund by day 9 p.i., but MAwt infection was not lethal 
in C57BL/6 or 129 control mice (Fig. 3a,c), as has been previously 
reported22,26. Rag−/− and SCID mice maintained detectable amounts 
of MAwt and MA-ExoN virus for 14 d (Rag−/−) or 60 d (SCID) beyond 
the background controls (Fig. 3d,e) but showed no signs of illness 
over the course of the experiment despite a lack of viral clearance, 
expanding earlier reports from our laboratory that MAwt does not 
clear from Rag−/− mice26. The rapid clearance of MA-ExoN infection 
from Stat1−/− mice (Fig. 3f) further supports the hypothesis that clear-
ance of SARS-CoV infection is dependent on both B and T cells27.
Mutation accumulation during persistent in vivo infection
Infection with both MAwt and MA-ExoN persisted for at least 60 d 
in SCID mice (Fig. 3e), potentially allowing for the most longitudinal 
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Figure 2 Weight loss and lung titer in BALB/c mice. (a–e) MA-ExoN and MAwt infections of 10-week-
old (a,b) and 12- to 14-month-old (c–e) female BALB/c mice. (a,c) Weight loss. Dark shapes and 
solid lines, MA-ExoN; white shapes and dashed lines, MAwt; diamonds, 102 PFU; squares, 103 PFU; 
triangles, 104 PFU. Error bars indicate s.d. (b,d) Lung titers. The titer for each mouse lung is indicated 
by an open circle; the mean titer of all mice at each time point is indicated by a horizontal bar.  
Days p.i. are indicated on the x axes; 2log, 3log and 4log indicate the MOIs of each virus (102, 103 or  
104 PFU, respectively). (e) Survival within aged mouse groups, calculated as the percentage of 
surviving mice compared to the total number of mice remaining on each day of the experiment.  
Line weights and symbols are as in a and c.
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Figure 3 Weight loss and lung titer in young immunocompromised mice. 
(a–c) MA-ExoN and MAwt infections of 10-week-old Rag−/− (a), SCID (b) and 
Stat1−/− (c) mice. C57BL/6 (a), BALB/c (b) and 129 (c) mice were included 
as background controls. Weight loss is shown. Dark shapes and solid lines, 
immunocompromised mice; white shapes and dashed lines, background 
control mice; circles, MA-ExoN; squares, MAwt. Error bars indicate s.d.  
(d–f) Lung titers for Rag−/− (d), SCID (e) and Stat1−/− (f) mice and 
background controls. The titer of each mouse lung is indicated by an  
open circle; the mean of all titers at each time point is indicated by a 
horizontal bar. Days p.i. are indicated on the x axes.
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cycles of replication and lowest immune barriers to the emergence 
of mutations conferring increased fitness, reversion to virulence and 
fidelity-compensating changes of any of the groups examined. To 
test this, we sequenced viral genomes from viral plaques grown from 
SCID mouse lung homogenates at 30 d p.i. (Fig. 4 and Supplementary 
Table 2). We identified a total of 14 consensus mutations (~100,000 nt) 
for MAwt, with 3 mutations shared in two or three genomes, result-
ing in 11 distinct mutations (4 synonymous and 7 nonsynonymous). 
For MA-ExoN, the engineered inactivation mutations were main-
tained. In contrast to MAwt, MA-ExoN plaques contained a total of 
91 mutations (89 distinct: 32 synonymous and 57 nonsynonymous), 
corresponding to a 9.6-fold higher total mutation accumulation 
compared to MAwt.
We compared mutation accumulations across two separate 
regions (open reading frame 1a (ORF1a), nucleotides 493–8603, and 
ORF1b, nucleotides 12915–16520; Supplementary Figs. 2 and 3 and 
Supplementary Table 2) for statistical determinations. Mutation 
accumulations were significantly higher in MA-ExoN–infected mice 
for both regions (P < 0.01). Additionally, there was a mean 18.3-fold 
increased accumulation for MA-ExoN across the ORF1a region. 
When we normalized the accumulations of mutations per 10 kb, MA-
ExoN mutation accumulations in the ORF1a compared to the ORF1b 
region were not significantly different (P = 0.340) but remained 
significantly increased compared to the accumulation in MAwt 
(P < 0.001 for both ORF1a and ORF1b). We identified no new 
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Figure 4 Mutation accumulation in infected SCID mice at 30 d p.i.  
The SARS-CoV genome is depicted at the top. The nsp14 ExoN coding 
region is denoted by a purple box, with the inactivating amino acid 
changes indicated above the schematic. The receptor-binding domain 
(RBD) is denoted by a black box. Individual SCID mouse genome 
sequences are represented by black horizontal lines. Dashed lines 
separate the nonstructural protein sequences in ORF1 and downstream 
ORFs. Mutations are indicated by lollipop shapes colored as follows: blue, 
synonymous, unique to one sequence; light blue, synonymous, present in 
three sequences; red, nonsynonymous, unique to one sequence; green, 
synonymous, present in two sequences; purple, nsp14 ExoN inactivation 
mutations. Mutations that alter the size of an ORF are indicated by a red 
∆ (deletion) or a red S (stop codon). Genome sizes, ORF and nonstructural 
protein boundaries and mutation marker placements are approximate.
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Figure 5 Virulence of passaged MA-ExoN and MAwt viruses.  
(a–c) MA-ExoN and MAwt serial infections of 12-month-old  
female BALB/c mice. Passages (P) are indicated on the x axes.  
(a) Serial passage after 24 h. (b,c) Serial passage after 72 h.  
(a,b) Lung titers are shown, with average titers indicated by bars.  
In the 72-h passage, MAwt-infected mice died by day 3 of  
passage 2; thus, the viruses were not passaged further.  
(c) Weight loss in the mice infected in the 72-h passage is shown.  
Error bars indicate s.d. (d) MA-ExoN (24-h passage 8 and 72-h  
passage 3) and MAwt (passage 1) infections of 12-month-old  
female BALB/c mice. Weight loss is shown. Error bars indicate s.d.  
(e) Infections of 10-week-old female BALB/c mice with MA-ExoN  
and MAwt population viruses isolated from SCID mice at 30 d p.i.;  
weight loss is shown. Dashed line, mock (PBS) inoculation; dark  
shapes and solid lines, MA-ExoN; white shapes and solid lines, MAwt.  
For each virus, lungs from three separate mice were harvested (mouse 1–mouse 3), and viruses were subsequently inoculated without plaque 
purification (population); circles, mouse 1 populations (pop 1); squares, mouse 2 populations (pop 2); triangles, mouse 3 populations (pop 3).  
(f) Weight loss in 11-month-old female BALB/c mice infected with MA-ExoN 2.1 (with C16999A) or MA-ExoN 3.1 (without C16999A) plaque isolates 
from SCID mice after 30 d of infection (SCID30). Squares, SCID30 MA-ExoN 2.1; circles, SCID30 MA-ExoN 3.1. Error bars indicate s.d.
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mutations in any of the three MA-ExoN plaques, suggesting no obliga-
tory or consistent pattern of adaptation or mutational bias. The most 
prevalent mutation identified (C16999M) was also present in viral 
stocks as a polymorphism; however, its frequency in the viral popula-
tion remained stable (~40%) both in vitro and in vivo and in experi-
ments with both BALB/c and SCID mice (Supplementary Tables 2 
and 3 and data not shown). The results from persistent ExoN infection 
over 30 d were consistent with the results from passage of SARS-
ExoN virus in culture: the ratios of accumulation of unique mutations 
(MA-ExoN:MAwt) during replication in SCID mice ranged from 
~9.6:1 to 18.3:1, which is similar to the ratio measured between SARS-
ExoN and SARS-CoV in culture16.
MA-ExoN resists reversion to virulence in vivo
To test the resistance to reversion to virulence during passage in vivo, 
we subjected MAwt and MA-ExoN to both short and long serial pas-
sages (24 h and 72 h per passage, respectively) in aged BALB/c mice 
(Fig. 5). In both groups, viral titer remained stable from passage to 
passage (Fig. 5a,b); additionally, viral plaque phenotypes were pre-
served, and the ExoN-inactivating mutations and amino acid substi-
tutions were maintained (data not shown). In contrast, whereas MAwt 
titer remained stable over the 24-h serial passage, mice inoculated with 
lung homogenates from the 72-h passage died by day 3 in passage 2 
(Fig. 5b). Although MA-ExoN titer remained stable over the 72-h pas-
sage, mouse weights did not decrease during infection after passage 1 
(Fig. 5c). Notably, there was no evidence of a gain of virulence with 
serial passage in the MA-ExoN pathogenesis model: when aged mice 
were infected with lung homogenates from each of the final 24-h and 
72-h passages, mice infected with MA-ExoN passages lost no or little 
weight, and MAwt-infected mice became moribund (Fig. 5d).
To test whether persistent MA-ExoN infection could result in phe-
notypic reversion to virulence, we used viruses harvested from SCID 
mice at day 30 p.i. to infect young BALB/c mice (Fig. 5e). MAwt-
infected mice showed signs of morbidity (weight loss, hunched pos-
ture and ruffled fur) but recovered. In contrast, MA-ExoN–infected 
mice showed no clinical signs of illness, as in the initial infection 
(Fig. 2a). Additionally, plaques containing different mutational sub-
sets were identically attenuated after re-infection of BALB/c mice 
(Fig. 5f). These results demonstrate that after 30 d of persistent infec-
tion, the ExoN mutator phenotype did not revert to virulence despite 
the greatly increased mutation rate and population diversity.
MA-ExoN vaccination protects mice from lethal challenge
Aged mice mount poor productive immune responses to SARS-CoV 
vaccines and remain highly susceptible to severe disease and lethal 
infection24,28, thus representing the most sensitive means to measure 
vaccine efficacy against lethal SARS-CoV infection. To test the effi-
cacy of the MA-ExoN mutant as a possible vaccine against lethal chal-
lenge, we vaccinated aged BALB/c mice with MA-ExoN and allowed 
them to recover from infection. We then challenged the mice with 
a lethal dose of MAwt (Fig. 6). Mock-vaccinated mice succumbed 
to MAwt challenge by day 3 p.i. and had high lung titers (Fig. 6a,b); 
however, mice vaccinated with MA-ExoN were protected from ill-
ness (Fig. 6a). Further, in contrast to other vaccine platforms24,28,29, 
MA-ExoN–vaccinated mice had no detectable lung titers 2 d after 
challenge (Fig. 6b).
Additionally, mice vaccinated with MA-ExoN generated high 
amounts of neutralizing antibodies (mean, 1:311 ± 37.5 reciprocal 
50% neutralization titer) (Fig. 6c). The minimal neutralizing titers for 
protection against SARS-CoV infection in mice have been reported as 
1:25–1:49 (ref. 30). Thus, even with a single vaccination, MA-ExoN 
provided complete protection against lethal challenge in a susceptible, 
immunosenescent mouse model of lethal SARS-CoV infection. To our 
knowledge, the MA-ExoN virus is the first approach to SARS-CoV 
immunization that fully protects against clinical disease and viral 
replication in an aged mouse model24,28,29.
DISCUSSION
Live, attenuated vaccines have substantially reduced the global disease 
burden associated with viral infections, including, for example, those 
of measles, mumps, rubella, polio, yellow fever and chickenpox9,15. 
However, live, attenuated vaccines carry several risks, including pri-
mary or secondary reversion to a virulent phenotype, as in the case of 
poliovirus9. In fact, attenuated phenotypes encounter natural selective 
pressures for reversion that can cause outbreaks of disease in unvac-
cinated populations31.
RNA virus replication fidelity has evolved to balance genome 
diversity and stability; therefore, inactivating an enzyme, such as 
nsp14-ExoN, that is responsible for high-fidelity replication could 
theoretically drive the virus toward instability, deleterious mutational 
diversity and decreased fitness in complex environments, which we 
observed here in vitro. It is possible that nsp14-ExoN may have other 
functions in viral RNA synthesis21; however, global impairment of 
viral RNA synthesis alone cannot explain the in vitro results and the 
attenuating phenotype in vivo.
It is not possible to fully separate defects caused by increased muta-
tion load from those resulting from the replication defect observed, 
and both probably contribute to the phenotype. However, our 
results are consistent with the hypothesis that both stable and evolv-
ing defects resulting from the mutator phenotype have irrevocably 
attenuated MA-ExoN. These defects could include (i) mutations 
that impair or terminate translation, replication and transcription; 
b
PBS
T
ite
r 
(lo
g 1
0 
P
F
U
 p
er
 lu
ng
)
MA-ExoN
Vaccine
8
7
6
5
4
3
2
1
0
c
S
er
um
 d
ilu
tio
n 
(1
:x
)
PBS MA-ExoN
400
350
300
250
200
150
100
50
0
105
a
100
95
90
85
80
0 1 2 3
Time (d p.i.)
MA-ExoN 4log
vaccine
MA-ExoN 2.5log
vaccine
PBS
4 5 6 7
P
er
ce
nt
ag
e 
in
iti
al
 m
as
s
Figure 6 MA-ExoN vaccination protects from 
lethal challenge. (a,b) Low-passage MA-ExoN 
and mock (PBS) vaccinations of 12-month-old  
female BALB/c mice followed by lethal 
challenge with MAwt. (a) Weight loss in 
challenged mice. Dark circles, 104 PFU  
MA-ExoN vaccination; white circles, 102.5  
PFU MA-ExoN vaccination; dark triangles,  
PBS vaccination. Error bars indicate s.d.  
(b) Lung titers at day 2 after challenge. ExoN 
was given at a 2.5log (102.5 PFU) vaccination. 
The mean titer is indicated by a bar in each  
group. (c) Fifty-percent plaque reduction neutralization titer (PRNT50) assay using sera from PBS-vaccinated and MA-ExoN–vaccinated mice to 
neutralize MAwt. Reciprocal dilutions capable of effecting 50% plaque reduction are shown by circles; mean reciprocal dilutions are indicated by a bar 
for each group. The limit of detection for each assay, if given, is indicated by a dashed line.
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(ii) mutations that impair or abolish protein functions; or (iii) changes 
in RNA polymerase processivity in the presence of an inactivated 
proofreading exonuclease. These combined impairments may be 
manifested with CoV ExoN mutants, as the high number of accumu-
lated mutations per genome is unprecedented among viral mutator 
strains. Indeed, the phenotype observed with CoV ExoN inactivation 
is similar to those reported for other polymerase complexes with inac-
tivated exonucleases, such as human mitochondrial DNA polymerase 
γ (pol γ)32,33 and bacteriophage T7 DNA polymerase34–36. In pol 
γ studies, the loss of proofreading was associated with impaired 
polymerase activity in a manner that was probably causal, impossible 
to uncouple and characterized by decreased speed, increased template 
dissociation and restricted access of nucleotides to the polymerase 
active site32,33. For CoVs, the high levels of iterative amplification of 
both genomic and subgenomic RNA would further accelerate these 
 deleterious processes by providing aberrant templates. The loss of ExoN 
proofreading would continuously generate new potentially attenuating 
alleles, and defective genomes and would reduce both genome fitness 
and the risks for primary and secondary reversions to virulence.
In this study, we demonstrate that MA-ExoN is attenuated in mice 
and that the mutant clears rapidly in the presence of an adaptive 
immune response. Although our in vivo experiments with MAwt 
recapitulated many of the phenotypes observed in aged and immuno-
compromised human populations, additional testing of MA-ExoN as 
a vaccine in primates will be necessary to further confirm its stability 
in vivo37. Experiments in SCID mice with persistent MA-ExoN infec-
tion verified the accumulation of mutations across the genome without 
evidence for the selection of either phenotypic virulence-enhancing 
alleles or primary genotypic reversion. Viruses harvested after pas-
sage remained avirulent, supporting the conclusions that (i) selection 
for virulence is not occurring; (ii) selection is being outcompeted 
by the gradual accumulation of attenuating mutations in individual 
genomes or the population mutational swarm; or (iii) the mutant is 
unable to generate or select for either fast-growing or slow-clearing 
viruses that are also more virulent. Not surprisingly, we identified a 
limited number of polymorphisms in the MA-ExoN virus stock that 
we used in subsequent experiments. Viruses with and without these 
mutations were fully attenuated in vivo, and the mutations were also 
maintained in lungs in the same frequencies as in the virus stock, 
suggesting that they were not selected against during passage in vivo. 
Thus, no single mutation or polymorphism could be clearly linked to 
viral attenuation except for the ExoN inactivation.
Notably, we have shown that MA-ExoN vaccinations are completely 
protective against replication and lethal challenge in aged BALB/c 
mice, the SARS-CoV mouse pathogenesis model that captures most of 
the severe clinical disease outcomes in human infections. Additionally, 
neutralization titers were equivalent or superior to those reported in 
studies of two-dose alphavirus replicon S glycoprotein vaccines and 
killed vaccines containing alum, with the additional advantage of pro-
tecting against virus replication and clinical disease24,28,29.
Live, attenuated vaccines must have two characteristics, aside from 
the capacity to elicit a protective immune response: resistance to pri-
mary reversion and stable attenuation at secondary sites. We have 
demonstrated that MA-ExoN has both of these characteristics. In 
all circumstances, the engineered inactivation mutations were main-
tained, indicating that exonuclease activity is not crucial for the virus 
life cycle and that the 4-nt, 2–amino acid change presents a substantial 
barrier to primary reversion; further, the passage experiments suggest 
that the virus lacks redundant or complementing mechanisms to fully 
restore the loss of ExoN activity. In addition, MA-ExoN harvested 
from persistently infected SCID mice retained an attenuated pheno-
type when re-inoculated into young BALB/c mice, suggesting that 
persistence does not select for virulence. Future studies are necessary 
to address whether additional modifications could enhance and sta-
bilize the attenuated phenotype by reducing the likelihood of gain of 
function by homologous recombination, such as introduction of the 
ExoN inactivation in a background with rewired transcriptional regu-
latory sequences38, which could increase resistance to reversion.
The inactivation of putative viral proofreading components in the 
pursuit of a stable vaccine constitutes a paradigm that has high poten-
tial to be broadly applicable to those members of the Nidovirales order 
with an exonuclease activity. In a time when metagenomics studies 
inform us of the likelihood of future viral emergence events—viruses 
that have the potential to afflict the human population much as SARS-
CoV did in 2002–2003—the design and ready implementation of an 
attenuation strategy that can be rapidly applied to any emerging CoV 
potentially represents a major advance in the preservation of pub-
lic health. These data should also encourage the pursuit of fidelity-
impairing mutations in the replicase proteins of other RNA viruses 
as potential targets or the use of CoVs as vaccine vectors for rational 
vaccine design.
METhODS
Methods and any associated references are available in the online 
version of the paper.
Accession codes. Plaque-purified MA-ExoN isolate sequences are 
deposited in GenBank under the following accession codes: FJ882942; 
FJ882943; FJ882945; FJ882948; FJ882951; FJ882952; FJ882953; 
FJ882957; FJ882958; FJ882959; FJ882961; FJ882962; HQ890526; 
HQ890527; HQ890528; HQ890529; HQ890530; HQ890531; 
HQ890532; HQ890533; HQ890534; HQ890535; HQ890536; 
HQ890537; HQ890538; HQ890539; HQ890540; HQ890541; 
HQ890542; HQ890543; HQ890544; HQ890545; HQ890546; JF292902; 
JF292903; JF292904; JF292905; JF292906; JF292907; JF292908; 
JF292909; JF292910; JF292911; JF292912; JF292913; JF292914; 
JF292915; JF292916; JF292917; JF292918; JF292919; and JF292920.
Note: Supplementary information is available in the online version of the paper.
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ONLINE METhODS
Construction of SARS D plasmid with ExoN and mouse-adapted mutations. 
A SARS-CoV D plasmid was constructed by restriction digestion and ligation 
of existing SARS D–ExoNI16 and SARS D mouse-adapted23 plasmids. Briefly, 
both plasmids were restriction digested with BstB I and Xba I enzymes. After 
treatment of the digested SARS D–ExoNI plasmid with Antarctic Phosphatase 
(New England BioLabs, Ipswitch, MA, USA), fragments were isolated, puri-
fied and ligated together using T4 DNA Ligase overnight at 4 °C as described 
previously39. Colonies were screened for proper insert size by restriction diges-
tion and electrophoresis, and the presence of the appropriate mutations was 
verified by sequencing.
Generation of SARS-CoV MA-ExoN mutant virus. Virus containing the ExoNI 
inactivation and mouse-adapted mutations within the viral coding sequence was 
produced using the infectious complementary DNA (cDNA) assembly strat-
egy for SARS-CoV as previously described39,40. ExoN viruses were kept at low 
passage (one passage past virus rescue, P1) to minimize the accumulation of 
mutations in cell culture. For this study, an equivalently low-passaged MAwt 
virus was used for comparison.
In vitro passage series and viral growth and plaque assays. MAwt and 
MA-ExoN viruses were grown in Vero cells at MOI = 0.1 PFU per cell in all 
in vitro experiments, with the exception of the genome RNA quantification 
experiment, which was performed at MOI = 3 PFU per cell. Passage series 
and growth experiments were performed, and viral titers were determined as 
previously described16.
Competition assay. Vero cells were plated at 106 cells per well in six-well plates. 
Cells were infected at an MOI of 0.1 with combinations of MAwt and MA-ExoN 
at 1:1, 1:10 and 1:100 ratios favoring either MA-ExoN or MAwt and were incu-
bated for 24 h at 37 °C. After 24 h, 100-µl aliquots of each supernatant were 
passed to fresh six-well plates of Vero cells for five total successive passages, 
and infected monolayers were harvested in TRIzol (Invitrogen, Grand Island, 
NY, USA). After passages were complete, RNA was purified according to the 
manufacturer’s protocol, and first-strand cDNA was generated as described41. 
PCR products were produced using the primers S32F and S34R (Supplementary 
Table 4). Once the presence of single-band PCR products was verified by agarose 
gel electrophoresis and the yields were calculated by spectrometry, 100 ng of 
each product was restriction digested using BsrF I, which cuts in the nsp14-
ExoN engineered mutation site but not in the corresponding MAwt sequence. 
Digested products were resolved on a 1.7% agarose gel, and normalized relative 
percentages of MAwt and ExoN-MA digested products were calculated using 
ImageJ (http://rsbweb.nih.gov/ij/).
Quantification of genome RNA. Vero cells were infected with either MAwt or 
MA-ExoN at MOI = 3 PFU per cell. At 6, 12 and 24 h p.i., RNA was harvested 
in TRIzol and isolated according to the manufacturer’s protocol. First-strand 
cDNA was generated as described above, and real-time PCR was performed 
assessing for genome RNA using the primers 5′-AGCCAACCAACCTCGATCT 
CTTGT-3′ (forward) and 5′-TGACACCAAGAACAAGGCTCTCCA-3′ (reverse). 
cDNA was normalized using the GAPDH primers 5′-TGCACCACCAA 
CTGCTTAGC-3′ (forward) and 5′-GGCATGGACTGTGGTCATGAG-3′ 
(reverse)42. Normalized results were then compared as ratios of MA-ExoN to 
MAwt genomes using the ∆∆Ct method.
Infection of mice with SARS-CoV MAwt and MA-ExoN. All experimental 
protocols involving mice were reviewed and approved by the institutional ani-
mal care and use committee at the University of North Carolina, Chapel Hill. 
The following groups of mice were used: 10-week-old female BALB/c (Charles 
River Laboratories, Wilmington, MA, USA), 14-month-old female BALB/c 
(Harlan Laboratories, Indianapolis, IN, USA), 10-week-old female Stat1−/− 
(Taconic Farms, Hudson, NY, USA; stock 002045-M-F), 10-week-old female 
129S6/SvEvTac (Taconic; stock 129SVE-F), 10-week-old female Rag−/− (Jackson 
Labs, Bar Harbor, ME, USA; stock 002216), 10-week-old female C57BL/6 
(Jackson; stock 00064) and 10-week-old female SCID (Jackson; stock 001803). 
Mice were lightly anesthetized and infected intranasally with varying doses 
(102–104 PFU, depending on the experiment) of SARS-CoV MAwt or SARS-
CoV MA-ExoN. Mice were weighed daily, and on certain days specified in each 
experiment, a subset of mice in each group was euthanized, and their lungs were 
harvested for virus titer. Mice that dropped below 70% of their initial mass or 
were moribund were euthanized before their scheduled time points. Serial pas-
sages were inoculated as above for passage 1; subsequent passages were inocu-
lated with 50 µl of clarified lung homogenate (lungs were homogenized in 1 ml 
of PBS) from the previous passage. All experiments used n = 5 mice per virus 
per dosage per condition (if applicable) per time point, with the exception of 
experiments using immunocompromised mice, in which n = 3.
Determination of virus titer in infected mouse lungs. Lungs harvested for 
virus titer were weighed and homogenized in 1.0 ml PBS at 6,000 r.p.m. for 60 s 
in a MagnaLyser (Roche, Basel, Switzerland). Virus titers were determined by 
plaque assay on Vero cells as previously described39.
Determination of viral neutralization antibody titers in mouse sera. Mouse 
sera were heat inactivated for 30 min at 55 °C and then serially diluted to 1:100, 
1:200, 1:400, 1:800 and 1:1,600 in PBS to a volume of 125 µl. Next, 125 µl of PBS 
containing low-concentration MAwt (40 PFU) or high-concentration MAwt 
(240 PFU) was added to each serum dilution. The virus-serum mixtures were 
incubated at 37 °C for 30 min. After incubation, virus titers of the mixtures were 
determined by plaque assay as described39. We then calculated the PRNT50 val-
ues, the serum dilutions at which plaque formation was reduced by 50% relative 
to that of virus stock not treated with serum.
Viral genome sequencing. To determine the sequences of viral genomes present 
in SCID mouse lungs after 30 d of infection, plaques were isolated from lung 
samples from SCID mice at 30 d p.i. as described above. Briefly, once individual, 
well-resolved viral plaques were visible, they were harvested by collecting the 
agarose plugs above them using a 200-µl pipette tip. Each agarose plug was 
dropped in 0.5 ml PBS, allowed to diffuse for 24 h at 4 °C and then applied to 
~70% confluent monolayers of Vero cells in T25 flasks and incubated for 48 h 
at 37 °C. Infected cell monolayers were then harvested in 1 ml TRIzol. First-
strand cDNA was generated as described41. Amplicons of the viral genomes 
were generated as follows: for whole-genome sequencing (amplicons 1–13) 
and partial-genome sequencing (amplicons A–G, X and Y), the primer pairs 
indicated in Supplementary Table 4 were used in a 50-µl PCR reaction using 
Phusion polymerase (New England BioLabs). Five microliters of each PCR reac-
tion were electrophoresed on agarose gels to verify the presence of correctly sized 
amplicons, and PCR products were purified using a Qiagen PCR Purification 
Kit (Qiagen, Valencia, CA, USA). Amplicons were then sequenced using the 
corresponding primer sets for each amplicon, as indicated in Supplementary 
Table 4. Sequence results were analyzed using Geneious Pro 5.3.6 (Biomatters, 
Auckland, New Zealand) and Serial Cloner 2.1 (SerialBasics, http://serialbasics.
free.fr/Home/Home.html).
Statistical analyses. Statistical analyses were performed using the Mann-
Whitney U test (http://elegans.som.vcu.edu/~leon/stats/utest.html). Significance 
was set at P < 0.05.
39. Yount, B. et al. Reverse genetics with a full length infectious cDNA of the severe 
acute respiratory syndrome coronavirus. Proc. Natl. Acad. Sci. USA 100, 
12995–13000 (2003).
40. Graham, R.L., Sims, A.C., Brockway, S.M., Baric, R.S. & Denison, M.R. The nsp2 
replicase proteins of murine hepatitis virus and severe acute respiratory syndrome 
coronavirus are dispensable for viral replication. J. Virol. 79, 13399–13411 
(2005).
41. Becker, M.M. et al. Synthetic recombinant bat SARS-like coronavirus is infectious 
in cultured cells and in mice. Proc. Natl. Acad. Sci. USA 105, 19944–19949 
(2008).
42. Chey, S., Claus, C. & Liebert, U.G. Validation and application of normalization 
factors for gene expression studies in rubella virus–infected cell lines with 
quantitative real-time PCR. J. Cell. Biochem. 110, 118–128 (2010).
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